Evidence map›Paper›PMID 35912641›Full record

ArticleMolecular genetics & genomic medicine2022

Array genotyping as diagnostic approach in medical genetics.

Martina Witsch-Baumgartner, Gunda Schwaninger, Simon Schnaiter, Franziska Kollmann, Silja Burkhard, Rebekka Gröbner, Beatrix Mühlegger, Esther Schamschula, Peter Kirchmeier, Johannes Zschocke

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Opportunistic Screening of High-Risk Breast Cancer Variants in Hospital Biobank Setting.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  2. Article
  3. Article
  4. Array genotyping as diagnostic approach in medical genetics.Molecular genetics & genomic medicine · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Martina Witsch-BaumgartnerInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Gunda SchwaningerInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Simon SchnaiterInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Franziska KollmannInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Silja BurkhardInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Rebekka GröbnerInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Beatrix MühleggerInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Esther SchamschulaInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Peter KirchmeierJSI Medical Systems GmbH, Ettenheim, Germany.
Johannes ZschockeInstitute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.ORCID 0000-0002-0046-8274
Innsbruck Medical University · ATUniversity Medical Centre Mannheim · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genotyping arrays are by far the most widely used genetic tests but are not generally utilized for diagnostic purposes in a medical context. In the present study, we examined the diagnostic value of a standard genotyping array (Illumina Global Screening Array) for a range of indications. Applications included stand-alone testing for specific variants (32 variants in 10 genes), first-tier array variant screening for monogenic conditions (10 different autosomal recessive metabolic diseases), and diagnostic workup for specific conditions caused by variants in multiple genes (suspected familial breast and ovarian cancer, and hypercholesterolemia). Our analyses showed a high analytical sensitivity and specificity of array-based analyses for validated and non-validated variants, and identified pitfalls that require attention. Ethical-legal assessment highlighted the need for a software solution that allows for individual indication-based consent and the reliable exclusion of non-consented results. Cost/time assessment revealed excellent performance of diagnostic array analyses, depending on indication, proband data, and array design. We have implemented some analyses in our diagnostic portfolio, but array optimization is required for the implementation of other indications.

Indexed as

Genetics, MedicalGenetic TestingGenotypeHigh-Throughput Nucleotide SequencingHumansSoftwareDNA arraygenetic testgenotypingscreeningsingle nucleotide variants

Identifiers

PMID35912641
PMCPMC9482391
OpenAlexW4289202327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.